Evidence map›Paper›PMID 32417768›Full record

ReviewHuman antibodies2021

Zero tolerance for complacency by government of West African countries in the face of COVID-19.

O Erhabor, T Erhabor, T C Adias, G C Okara, M Retsky

Open access · greenAbstract readReview
In one paragraph

Review in Human antibodies, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 2 countries.

O ErhaborDepartment of Haematology, SMLS, Usmanu Danfodiyo University, Sokoto, Nigeria.
T ErhaborMedical Laboratory Science Council of Nigeria, Nigeria.
T C AdiasFederal University Otuoke Bayelsa State, Nigeria.
G C OkaraWest African Postgraduate College of Medical Laboratory Science, Nigeria.
M RetskyHarvard School of Public Health, Boston, MA, USA.
Federal University Otuoke · NGHarvard University · USMedical Laboratory Science Council of Nigeria · NGNational Postgraduate Medical College of Nigeria · NGUsmanu Danfodiyo University · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A novel Coronavirus (SARS-CoV-2) causing a cluster of respiratory infections (Coronavirus Disease 2019, COVID-19) first discovered in Wuhan, China, is responsible for a new illness that has been found to affect the lungs and airways of patients with associated symptoms of fever, cough and shortness of breath. In the light of few cases recorded so far in West Africa there is tendency for complacency. The region needs to make strategic plans based on available evidence to enable them effectively deal with this rapidly evolving pandemic. At this very moment countries like China, Italy, France, Spain, Iran, UK and many others are witnessing sustained and intensive community transmission of this virus and increasing numbers of severe disease and death particularly among elderly patients with other comorbidities. The reality of the seriousness of this pandemic is alarming. Government of member states of ECOWAS need to prepare themselves by building capacity as well as implement evidenced-based steps to mitigate this rapidly evolving pandemic by testing persons presenting with symptoms (fever, cough and shortness of breath), isolating and treating those found positive, tracing and quarantining contacts, implementing social distancing as well as optimizing human and material endowment to allow healthcare workers offer safe quality clinical care for affected patients to prevent secondary infection among healthcare workers.

Indexed as

PandemicsAfrica, WesternAge FactorsAmericasAsiaCivil DefenseCOVID-19EuropeGlobal HealthHumansIncidencePersonal Protective EquipmentPhysical DistancingQuarantineSARS-CoV-2complacencyCOVID-19 pandemicgovernmentWest AfricaZero tolerance

Identifiers

PMID32417768
PMCPMC8150474
OpenAlexW3025121521

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.